229 related articles for article (PubMed ID: 15608154)
1. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency.
Kösel S; Burggraf S; Fingerhut R; Dörr HG; Roscher AA; Olgemöller B
Clin Chem; 2005 Feb; 51(2):298-304. PubMed ID: 15608154
[TBL] [Abstract][Full Text] [Related]
2. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants.
Nordenström A; Wedell A; Hagenfeldt L; Marcus C; Larsson A
Pediatrics; 2001 Oct; 108(4):E68. PubMed ID: 11581476
[TBL] [Abstract][Full Text] [Related]
3. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
Janzen N; Peter M; Sander S; Steuerwald U; Terhardt M; Holtkamp U; Sander J
J Clin Endocrinol Metab; 2007 Jul; 92(7):2581-9. PubMed ID: 17456574
[TBL] [Abstract][Full Text] [Related]
4. High frequency of non-classical congenital adrenal hyperplasia form among children with persistently elevated levels of 17-hydroxyprogesterone after newborn screening.
Castro PS; Rassi TO; Araujo RF; Pezzuti IL; Rodrigues AS; Bachega TASS; Silva IN
J Pediatr Endocrinol Metab; 2019 May; 32(5):499-504. PubMed ID: 31028712
[TBL] [Abstract][Full Text] [Related]
5. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia.
Cavarzere P; Samara-Boustani D; Flechtner I; Dechaux M; Elie C; Tardy V; Morel Y; Polak M
Eur J Endocrinol; 2009 Aug; 161(2):285-92. PubMed ID: 19451212
[TBL] [Abstract][Full Text] [Related]
6. False positive rate in newborn screening for congenital adrenal hyperplasia (CAH)-ether extraction reveals two distinct reasons for elevated 17alpha-hydroxyprogesterone (17-OHP) values.
Fingerhut R
Steroids; 2009 Aug; 74(8):662-5. PubMed ID: 19463687
[TBL] [Abstract][Full Text] [Related]
7. Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.
Stroek K; Ruiter A; van der Linde A; Ackermans M; Bouva MJ; Engel H; Jakobs B; Kemper EA; van den Akker ELT; van Albada ME; Bocca G; Finken MJJ; Hannema SE; Mieke Houdijk ECA; van der Kamp HJ; van Tellingen V; Paul van Trotsenburg AS; Zwaveling-Soonawala N; Bosch AM; de Jonge R; Heijboer AC; Claahsen-van der Grinten HL; Boelen A
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4487-e4496. PubMed ID: 34171085
[TBL] [Abstract][Full Text] [Related]
8. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
Seo JY; Park HD; Kim JW; Oh HJ; Yang JS; Chang YS; Park WS; Lee SY
J Perinat Med; 2014 Jan; 42(1):121-7. PubMed ID: 23989111
[TBL] [Abstract][Full Text] [Related]
9. The actual incidence of congenital adrenal hyperplasia in Brazil may not be as high as inferred--an estimate based on a public neonatal screening program in the state of Goiás.
Silveira EL; dos Santos EP; Bachega TA; van der Linden Nader I; Gross JL; Elnecave RH
J Pediatr Endocrinol Metab; 2008 May; 21(5):455-60. PubMed ID: 18655527
[TBL] [Abstract][Full Text] [Related]
10. Hormonal evaluation and mutation screening for steroid 21-hydroxylase deficiency in patients with unilateral and bilateral adrenal incidentalomas.
Patócs A; Tóth M; Barta C; Sasvári-Székely M; Varga I; Szücs N; Jakab C; Gláz E; Rácz K
Eur J Endocrinol; 2002 Sep; 147(3):349-55. PubMed ID: 12213672
[TBL] [Abstract][Full Text] [Related]
11. Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.
Fitness J; Dixit N; Webster D; Torresani T; Pergolizzi R; Speiser PW; Day DJ
J Clin Endocrinol Metab; 1999 Mar; 84(3):960-6. PubMed ID: 10084579
[TBL] [Abstract][Full Text] [Related]
12. Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne.
Ostlere LS; Rumsby G; Holownia P; Jacobs HS; Rustin MH; Honour JW
Clin Endocrinol (Oxf); 1998 Feb; 48(2):209-15. PubMed ID: 9579234
[TBL] [Abstract][Full Text] [Related]
13. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.
Allen DB; Hoffman GL; Fitzpatrick P; Laessig R; Maby S; Slyper A
J Pediatr; 1997 Jan; 130(1):128-33. PubMed ID: 9003862
[TBL] [Abstract][Full Text] [Related]
14. Neonatal screening: identification of children with 11β-hydroxylase deficiency by second-tier testing.
Janzen N; Riepe FG; Peter M; Sander S; Steuerwald U; Korsch E; Krull F; Müller HL; Heger S; Brack C; Sander J
Horm Res Paediatr; 2012; 77(3):195-9. PubMed ID: 22508345
[TBL] [Abstract][Full Text] [Related]
15. The influence of seasonality and manufacturer kit lot changes on 17α-hydroxyprogesterone measurements and referral rates of congenital adrenal hyperplasia in newborns.
Pearce M; Dauerer E; DiRienzo AG; Caggana M; Tavakoli NP
Eur J Pediatr; 2017 Jan; 176(1):121-129. PubMed ID: 27900477
[TBL] [Abstract][Full Text] [Related]
16. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
Kopacek C; de Castro SM; Prado MJ; da Silva CM; Beltrão LA; Spritzer PM
BMC Pediatr; 2017 Jan; 17(1):22. PubMed ID: 28095810
[TBL] [Abstract][Full Text] [Related]
17. Reverse-hybridization assay for rapid detection of common CYP21A2 mutations in dried blood spots from newborns with elevated 17-OH progesterone.
Németh S; Riedl S; Kriegshäuser G; Baumgartner-Parzer S; Concolino P; Neocleous V; Phylactou LA; Borucka-Mankiewicz M; Onay H; Tukun A; Oberkanins C
Clin Chim Acta; 2012 Dec; 414():211-4. PubMed ID: 22985688
[TBL] [Abstract][Full Text] [Related]
18. Reverse dot-blot hybridization as an improved tool for the molecular diagnosis of point mutations in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency.
Yang YP; Corley N; Garcia-Heras J
Mol Diagn; 2001 Sep; 6(3):193-9. PubMed ID: 11571713
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance.
Votava F; Novotna D; Kracmar P; Vinohradska H; Stahlova-Hrabincova E; Vrzalova Z; Neumann D; Malikova J; Lebl J; Matern D
Eur J Pediatr; 2012 Jun; 171(6):935-40. PubMed ID: 22234478
[TBL] [Abstract][Full Text] [Related]
20. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
Güran T; Tezel B; Gürbüz F; Selver Eklioğlu B; Hatipoğlu N; Kara C; Şimşek E; Çizmecioğlu FM; Ozon A; Baş F; Aydın M; Darendeliler F
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):13-23. PubMed ID: 30111524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
